Addressing a critical gap in women's health diagnostics, Mammogen, a predictive health company, has secured $30.0M in Series A funding. The capital infusion will accelerate the development of its RNA-powered molecular diagnostics platform, designed to enable earlier disease detection.
Mammogen's lead product candidate, genTRU-breast, is a blood-based assay providing clinically actionable real-time biologic signals for breast cancer detection. This is particularly vital for women with dense breast tissue, where traditional screening methods often fall short. The company's platform, built on scalable RNA biomarker discovery, is also slated for expansion into additional women’s health applications.
